Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
[[:Category:Antiemetics|Antiemetic]] (1) ·
[[:Category:Antihistamines|First-generation antihistamine (piperazine)]] (1) ·
[[:Category:Antiparkinsonians|Antiparkinsonian]] (2) ·
[[:Category:Antiseptics|Antiseptic]] (1) ·
[[:Category:Antivertigo medicines|Antivertigo medicine]] (1) ·
[[:Category:Basal_insulins|Basal insulin]] (1) ·
[[:Category:Bisbiguanides|Bisbiguanide]] (1) ·
[[:Category:Dopamine agonists|Dopamine D2/D3 receptor agonist (non-ergot)]] (2) ·
[[:Category:Insulins|Insulin]] (1) ·
[[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant (centrally-acting)]] (1) ·
[[:Category:Tricyclic-related compounds|Tricyclic-related compound]] (1) ·
[[:Category:Ultra-long-acting_insulins|Ultra-long-acting insulin analog]] (1)
None (4) ·
'"`UNIQ--vote-00000013-QINU`"' Anticholinergic burden (dry mouth, blurred vision, urinary retention, cognitive effects) is the principal adverse-event concern and the basis for Beers-list cautions in elderly patients'"`UNIQ--ref-00000014-QINU`"'. (1) ·
'"`UNIQ--vote-00001356-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio'"`UNIQ--ref-00001357-QINU`"'. (1)
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) ·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"' (1) ·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) ·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1) ·
'"`UNIQ--vote-00001358-QINU`"', '"`UNIQ--vote-00001359-QINU`"' (1) ·
'"`UNIQ--vote-00001393-QINU`"', '"`UNIQ--vote-00001394-QINU`"', '"`UNIQ--vote-00001395-QINU`"', '"`UNIQ--vote-00001396-QINU`"', '"`UNIQ--vote-00001397-QINU`"' (1)
IR 5 mg PO TID; titrate to 10 mg TID if needed. Amrix ER 15 mg PO once daily. Off-label insomnia / fibromyalgia: 5-10 mg PO at bedtime (1) ·
Motion sickness: 25-50 mg PO 1 hour before travel, repeat every 24 hours as needed. Vertigo: 25-100 mg/day divided (1) ·
Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed (1) ·
Parkinson disease: 0.25 mg PO TID, titrate weekly. Restless legs syndrome: 0.25 mg PO 1-3 hours before bedtime, titrate to 4 mg/day if needed (1) ·
Surgical scrub 4% CHG; preop skin prep 2% CHG/70% isopropyl alcohol (ChloraPrep); ICU bathing 2% CHG daily; oral rinse 0.12% 15 mL twice daily for 30 seconds (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (1)
100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience) (1) ·
2%, 4% wash; 2% CHG/70% IPA applicators (ChloraPrep); 0.12%, 0.2% oral rinse; impregnated catheter dressings (1) ·
IR tablets 0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tablets 0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg (1) ·
IR tablets 0.25, 0.5, 1, 2, 3, 4, 5 mg; XL tablets 2, 4, 6, 8, 12 mg (1) ·
IR tablets 5, 7.5, 10 mg; Amrix ER capsules 15, 30 mg (1) ·
Tablets 12.5, 25 mg; chewable tablets 25 mg (1)
12-24 hours (IR); 24 hours (Amrix ER) (1) ·
12-24 hours (long for an antihistamine) (1) ·
>42 hours per dose (effectively flat once at steady state) (1) ·
Persistent activity 6+ hours (residual binding to skin and oral surfaces) (1) ·
TID dosing (IR); once-daily (ER) (1) ·
TID dosing (IR); once-daily (XL) (1)
18 hours (IR); 32-33 hours (ER)'"`UNIQ--ref-0000001A-QINU`"' (1) ·
8-12 hours (longer in elderly and renal impairment)'"`UNIQ--ref-0000001B-QINU`"' (1) ·
Not meaningfully described (negligible systemic absorption from intact skin or oral mucosa)'"`UNIQ--ref-00001398-QINU`"' (1) ·
~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)'"`UNIQ--ref-0000135A-QINU`"' (1) ·
~6 hours'"`UNIQ--ref-00000015-QINU`"' (1) ·
~6 hours'"`UNIQ--ref-00000018-QINU`"' (1)
>90% (oral)'"`UNIQ--ref-0000001C-QINU`"' (1) ·
Topical/oral local action with minimal systemic absorption'"`UNIQ--ref-00001399-QINU`"' (1) ·
~100% from subcutaneous depot (1) ·
~25% (oral)'"`UNIQ--ref-00000019-QINU`"' (1) ·
~33-55% (IR); reduced by food'"`UNIQ--ref-0000001B-QINU`"' (1) ·
~55% (oral)'"`UNIQ--ref-00000016-QINU`"' (1)
Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited human data; rarely indicated in pregnancy given the typical patient population.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Older agent with substantial use experience; observational signals reassuring for first-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
OTC (lower-concentration washes) and [[USLegal:Prescription only|Rx-only]] (Peridex oral rinse, ChloraPrep) in US (1) ·
[[USLegal:Over-the-counter|OTC]] as Bonine and Dramamine Less Drowsy; [[USLegal:Prescription only|Rx-only]] as Antivert (1) ·
[[USLegal:Prescription only|Rx-only]] in US (3) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, distinguishing it from the carisoprodol alternative for muscle spasm'"`UNIQ--ref-0000001C-QINU`"' (1)
Showing below up to 6 results in range #1 to #6.


